A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases Academic Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Indoles
  • Melanoma
  • Proto-Oncogene Proteins B-raf
  • Sulfonamides

abstract

  • Vemurafenib is active for BRAF-mutant intracranial melanoma metastases in an unselected patient population typical of routine oncologic practice. Patients with poor performance status appear to have poor outcomes despite vemurafenib therapy. Preliminary data indicate that co-occurring or secondary alterations in the phosphatidylinositol 3-kinase-AKT (PI3K-AKT) pathway are involved in resistance to RAF inhibition, thus providing a rationale for dual MAPK and PI3K-AKT pathway inhibition in this patient population.

publication date

  • May 8, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4492223

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2014-0012

PubMed ID

  • 25956405

Additional Document Info

start page

  • 789

end page

  • 97

volume

  • 20

number

  • 7